Pertinax Pharma Overview
- Founded
-
2015
- Status
-
Private
- Employees
-
1
- Latest Deal Type
-
Early Stage VC
- Latest Deal Amount
-
$447K
- Investors
-
6
Pertinax Pharma General Information
Description
Developer of antimicrobial technologies intended to be used in medical devices. The company's products can be incorporated into a wide range of medical device material substrates, including polymers and coatings, enabling healthcare professionals to offer longer antimicrobial and antifungal protection.
Contact Information
Website
www.pertinaxpharma.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Other Healthcare Technology Systems
Other Industries
Medical Supplies
Primary Office
- Research and Enterprise Development University Of Bristol
- 2nd Floor, Augustines Courtyard
- Bristol BS1 5DS
- England, United Kingdom
Pertinax Pharma Timeline
Pertinax Pharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Early Stage VC | 21-Mar-2019 | $447K | 00.000 | 00.000 | Completed | Generating Revenue |
| 7. Grant | 16-Jan-2019 | 000.00 | 00.00 | Completed | Generating Revenue | |
| 6. Early Stage VC | 11-Oct-2018 | 00.000 | 00.00 | 00.000 | Completed | Generating Revenue |
| 5. Seed Round | 15-Mar-2017 | 00000 | 00.000 | 00.000 | Completed | Startup |
| 4. Grant | 01-Jun-2016 | 000.00 | 00000 | Completed | Startup | |
| 3. Early Stage VC | 11-Apr-2016 | 00000 | 00000 | 00.000 | Completed | Startup |
| 2. Grant | 11-Mar-2016 | $768K | Completed | Startup | ||
| 1. Accelerator/Incubator | 01-Mar-2015 | Completed | Startup |
Pertinax Pharma Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| C Ordinary | 00,000 | 00.000000 | 000.00 | 000.00 | 00 | 000.00 | 00.000 | |
| A Ordinary | 00,000 | 00.000000 | 000.00 | 000.00 | 00 | 000.00 | 00.000 | |
| A Ordinary | 39,000 | $0.000132 | $21.1 | $21.1 | 1x | $21.1 | 11.66% | |
| A Ordinary | 36,958 | $0.000132 | $15.14 | $15.14 | 1x | $15.14 | 11.05% |
Pertinax Pharma Executive Team (3)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Michele Barbour Ph.D | Founder & Chief Executive Officer |
Pertinax Pharma Board Members (4)
| Name | Representing | Role | Since |
|---|---|---|---|
| Isabel Dodd Ph.D | Mercia Asset Management | Board Member | 000 0000 |
Pertinax Pharma Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Pertinax Pharma Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Innovation 4 Growth | Corporation | 000 0000 | 000000 0 | ||
| Mercia Asset Management | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Perivoli Innovations Trust | Venture Capital | Minority | 000 0000 | 000000 0 | |
| The Armourers and Brasiers | Not-For-Profit Venture Capital | 000 0000 | 000000 0 | ||
| Innovate UK | Government | 000 0000 | 000000 0 |